BioArctic Full Year 2024 Earnings: Beats Expectations

BioArctic (STO:BIOA B) Full Year 2024 Results

Key Financial Results

• Revenue: kr257.4m (down 58% from FY 2023).
• Net loss: kr177.1m (down by 177% from kr229.2m profit in FY 2023).
• kr2.00 loss per share (down from kr2.60 profit in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

BioArctic Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 9.8%.

Looking ahead, revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Sweden.

Performance of the Swedish Biotechs industry.

The company's shares are down 5.1% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 1 warning sign for BioArctic you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.